184 related articles for article (PubMed ID: 21235734)
1. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent.
Horibe T; Kohno M; Haramoto M; Ohara K; Kawakami K
J Transl Med; 2011 Jan; 9():8. PubMed ID: 21235734
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90.
Horibe T; Kawamoto M; Kohno M; Kawakami K
J Biosci Bioeng; 2012 Jul; 114(1):96-103. PubMed ID: 22425524
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cells.
Horibe T; Torisawa A; Kohno M; Kawakami K
Mol Cancer; 2012 Aug; 11():59. PubMed ID: 22913813
[TBL] [Abstract][Full Text] [Related]
4. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.
Horibe T; Torisawa A; Kohno M; Kawakami K
BMC Cancer; 2014 Aug; 14():615. PubMed ID: 25159299
[TBL] [Abstract][Full Text] [Related]
5. Specific Binding of Tetratricopeptide Repeat Proteins to Heat Shock Protein 70 (Hsp70) and Heat Shock Protein 90 (Hsp90) Is Regulated by Affinity and Phosphorylation.
Assimon VA; Southworth DR; Gestwicki JE
Biochemistry; 2015 Dec; 54(48):7120-31. PubMed ID: 26565746
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 can accommodate the simultaneous binding of the FKBP52 and HOP proteins.
Hildenbrand ZL; Molugu SK; Herrera N; Ramirez C; Xiao C; Bernal RA
Oncotarget; 2011; 2(1-2):43-58. PubMed ID: 21378414
[TBL] [Abstract][Full Text] [Related]
7. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
8. In silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent.
Gupta UK; Mahanta S; Paul S
Med Hypotheses; 2013 Nov; 81(5):853-61. PubMed ID: 24018284
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of the interaction of Hsp90 with its co-chaperone Hop.
Lott A; Oroz J; Zweckstetter M
Protein Sci; 2020 Dec; 29(12):2422-2432. PubMed ID: 33040396
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70.
Carrello A; Allan RK; Morgan SL; Owen BA; Mok D; Ward BK; Minchin RF; Toft DO; Ratajczak T
Cell Stress Chaperones; 2004; 9(2):167-81. PubMed ID: 15497503
[TBL] [Abstract][Full Text] [Related]
11. Ligand discrimination by TPR domains. Relevance and selectivity of EEVD-recognition in Hsp70 x Hop x Hsp90 complexes.
Brinker A; Scheufler C; Von Der Mulbe F; Fleckenstein B; Herrmann C; Jung G; Moarefi I; Hartl FU
J Biol Chem; 2002 May; 277(22):19265-75. PubMed ID: 11877417
[TBL] [Abstract][Full Text] [Related]
12. Generation of a selectively cytotoxic fusion protein against p53 mutated cancers.
Kousparou CA; Yiacoumi E; Deonarain MP; Epenetos AA
BMC Cancer; 2012 Aug; 12():338. PubMed ID: 22862878
[TBL] [Abstract][Full Text] [Related]
13. Tetratricopeptide repeat motif-mediated Hsc70-mSTI1 interaction. Molecular characterization of the critical contacts for successful binding and specificity.
Odunuga OO; Hornby JA; Bies C; Zimmermann R; Pugh DJ; Blatch GL
J Biol Chem; 2003 Feb; 278(9):6896-904. PubMed ID: 12482845
[TBL] [Abstract][Full Text] [Related]
14. Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches.
Darby JF; Vidler LR; Simpson PJ; Al-Lazikani B; Matthews SJ; Sharp SY; Pearl LH; Hoelder S; Workman P
Sci Rep; 2020 Sep; 10(1):16000. PubMed ID: 32994435
[TBL] [Abstract][Full Text] [Related]
15. Structural studies on the co-chaperone Hop and its complexes with Hsp90.
Onuoha SC; Coulstock ET; Grossmann JG; Jackson SE
J Mol Biol; 2008 Jun; 379(4):732-44. PubMed ID: 18485364
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
17. Rational design of shepherdin, a novel anticancer agent.
Plescia J; Salz W; Xia F; Pennati M; Zaffaroni N; Daidone MG; Meli M; Dohi T; Fortugno P; Nefedova Y; Gabrilovich DI; Colombo G; Altieri DC
Cancer Cell; 2005 May; 7(5):457-68. PubMed ID: 15894266
[TBL] [Abstract][Full Text] [Related]
18. A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines.
Pimienta G; Herbert KM; Regan L
Mol Pharm; 2011 Dec; 8(6):2252-61. PubMed ID: 21882818
[TBL] [Abstract][Full Text] [Related]
19. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
20. Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90.
Young JC; Obermann WM; Hartl FU
J Biol Chem; 1998 Jul; 273(29):18007-10. PubMed ID: 9660753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
